1. Introduction {#s0005}
===============

Published epidemiologic data for Menkes disease and its phenotypic variants are limited \[[@bb0005], [@bb0010], [@bb0015]\] and rely on case ascertainment and birth rates, which may each contain considerable sources of bias. Classic Menkes disease is an early-onset (6 to 8 weeks of age) neurodegenerative disorder of copper metabolism that features seizures, hypotonia, failure to thrive, hair and connective tissue abnormalities, and early death, often before three years of age \[[@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]\]. The illness is caused by severe loss-of-function mutations in *ATP7A*, an evolutionarily conserved copper-transporting ATPase \[[@bb0045]\]. Occipital horn syndrome and ATP7A-related distal motor neuropathy are allelic variants of Menkes disease that have less distinctive clincal and biochemical signs \[[@bb0050],[@bb0055]\] for which reasons diagnostic recognition may be delay or prevented.

We sought an unbiased estimate for the birth prevalence of Menkes disease and related X-linked recessive conditions \[[@bb0045], [@bb0050], [@bb0055]\] through an alternative, recently available approach that is considered less subject to bias, *i.e.*, population-based genomic data analysis \[[@bb0060], [@bb0065], [@bb0070], [@bb0075]\]. The Genome Aggregation Database (gnomAD) at Broad Institute, Massachusetts Institute of Technology, Cambridge, MA covers 125,748 exomes and 15,708 genomes from 141,456 unrelated individuals (<https://gnomad.broadinstitute.org/>) and lists all genetic variants and their allelic frequencies, as well as which variants are predicted to be disease-causing \[[@bb0080]\].

Untreated Menkes disease is associated with inexorable neurological decline beginning in early infancy; however, early treatment (by 10 to 28 days of age) with subcutaneous injections of Copper Histidinate for three years has been associated with improved clinical outcomes \[[@bb0085],[@bb0090]\]. Adeno-associated virus-mediated *ATP7A* gene addition provides a synergistic complementary effect in a mouse model of this disease \[[@bb0095],[@bb0100]\]. While newborn screening (NBS) for this condition is not yet available, the recent therapeutic advances imply the potential importance of early detection.

The Hardy-Weinberg equilibrium law predicts that, in populations with random mating, genotype frequencies are determined by the relative frequencies of alleles at a given locus, as summarized in the equation: p^2^ + 2pq + q^2^ \[[@bb0105]\]. The term p represents the frequency of normal alleles and q, the frequency of mutant alleles. For X-linked recessive loci such as Menkes/*ATP7A*, p^2^ represents a combination of healthy females and healthy males with normal alleles, and 2pq connotes the combination of heterozygous (carrier) females and affected males, each individual with one mutant X-chromosome. The final term (q^2^) can be dropped for X-linked loci such as *ATP7A*, since only females have two X-chromosomes, and females with two pathogenic *ATP7A* variants have never been reported.

Here, we apply Hardy-Weinberg principles \[[@bb0105]\] to *ATP7A* genomic data obtained from the largest and most diverse human population sample available \[[@bb0080]\], to re-evaluate the estimated birth prevalence of Menkes disease.

2. Methods {#s0010}
==========

We reviewed the canonical *ATP7A* transcript (ENST00000341514) in the current version of gnomAD (Version 2.1.1) (<https://gnomad.broadinstitute.org/gene/ENSG00000165240> (accessed December 17, 2019) for predicted severe loss-of-function and evaluated selected missense variants for potential pathogenicity using PolyPhen-2 *in silico* analyses, as well as REVEL and CADD ensemble analyses \[[@bb0110], [@bb0115], [@bb0120]\]. We applied the Hardy-Weinberg law \[[@bb0105]\] to assess the frequencies of normal and mutant *ATP7A* alleles, and calculated the estimated annual US birth prevalence of classic Menkes disease based on reliable birth statistics \[[@bb0125],[@bb0130]\]. A stringent REVEL cut-off value (0.85) was used to determine missense variant pathogencity \[[@bb0115]\].

3. Results {#s0015}
==========

The gnomAD database identifies 1106 variants among a maximum of 205,523 *ATP7A* alleles ([Table 1](#t0005){ref-type="table"}). Most variants noted are missense (43%). To estimate the frequency of pathogenic variants at the *ATP7A* locus, we analyzed loss-of-function and predicted pathogenic missense variants found in gnomAD. Four *ATP7A* variants, representing four independent alleles, were predicted as unequivocally loss-of-function alleles ([Table 2](#t0010){ref-type="table"}), out of a total of 205,523 sequenced. All occurred only in females, as expected for a X-linked recessive trait. Two other variants, both canonical splice acceptor site alterations were also reported in gnomAD as loss-of-function alleles, however both variants occurred in apparently healthy males \[[@bb0080]\].Table 1Distribution of All *ATP7A* Variants in gnomAD (v2.1.1).Table 1*ATP7A* VariantsNumber%Missense Variant48043.4%Intron Variant39836.0%Synonymous Variant17515.8%Splice Region Variant383.4%3 Prime UTR Variant70.6%Frameshift Variant20.2%Splice Acceptor Variant20.2%5 Prime UTR Variant10.1%Splice Donor Variant10.1%Stop Gained10.1%In-frame Deletion10.1%Total1106100.0%[^1]Table 2Predicted Loss-of-Function *ATP7A* Variants Reported in gnomAD (v2.1.1).Table 2Pathogenic variantVariant TYPEAllele number detected1.c.120, +1 g \> aCanonical splice donor site12.Gln200ProfsTer3Frameshift13.Arg201GlnfsTer23Frameshift14.Glu264TerNonsense1Total = 4 variant alleles/205,523 total alleles detected (0.0000194)

Using the Hardy-Weinberg law \[[@bb0105]\], the term q represents the frequency of mutant alleles, which, in this example for *ATP7A*, is estimated to be 4 in 205,523 or 0.0000194. The allelic frequency of p is equal to 1 minus q, *i.e.*, 1 minus 0.0000194, or 0.9999806. Therefore, the Hardy-Weinberg equation for *ATP7A* allelic frequencies is:$$p^{2} + \text{2pq} + q^{2} = 1$$$$\left( 0.9999806 \right)^{2} + 2\left( 0.9999806 \right)\left( 0.0000194 \right) + 0 = 1$$$$0.9999612 + 0.0000387 + 0 = 0.9999999$$

Based on this analysis, unaffected males and non-carrier females with normal *ATP7A* alleles are predicted to comprise 99.99% of the population under conditions of random mating.

Considering US annual birth rates (3.8 million per year, with slight male birth bias) \[[@bb0125],[@bb0130]\], an estimated 1,949,400 males and 1,850,600 females, comprising 5,650,600 *ATP7A* alleles and X chromosomes, are anticipated to be added to the US population annually. Based on the mutant allele frequency from the gnomAD database (q = 0.0000194), the number of abnormal *ATP7A* variants predicted each year among US newborns is 110 (0.0000194 × 5,650,600,), including both males and females. Given the slight birth bias toward male gender \[[@bb0015],[@bb0130]\], the annual number of male newborns with a complete loss-of-function *ATP7A* allele should approximate 56. This translates to a birth prevalence for classic Menkes disease of one in every 34,810 male births (1,949,400/ 56), based on the genomic data from gnomAD.

By way of comparison, we applied the same approach to a different X-linked recessive disorder, Duchenne Muscular Dystrophy, for which incidence data are better established due to longer lifespan. Analysis of gnomAD database entries for the *DMD* locus indicated 19 unequivocally loss-of-function alleles that occurred exclusively in females out of a total of 204,738 sequenced. Using the Hardy-Weinberg law \[[@bb0105]\], the term q represents the frequency of mutant alleles, which, in this example for *DMD*, is estimated to be 19 in 204,738 or 0.0000928. The allelic frequency of p is therefore 0.9999072. Therefore, the Hardy-Weinberg equation for *DMD* allelic frequencies is:$$p^{2} + \text{2pq} + q^{2} = 1$$$$\left( 0.9999072 \right)^{2} + 2\left( 0.9999072 \right)\left( 0.0000928 \right) + 0 = 1$$$$0.9998144 + 0.0001855 + 0 = 0.9999999$$

Based on this analysis, the predicted birth prevalence of DMD equals 1 in 7246 live male births, in reasonable agreement with population-based estimates (1 in 5000 newborn males) \[[@bb0135]\].

In addition to the four clearly pathogenic *ATP7A* variants, we identified 28 missense variants predicted by Polyphen-2 as potentially pathogenic and which were not found in males ([Table 3](#t0015){ref-type="table"}). REVEL and CADD ensemble analyses performed for these variants revealed nine with REVEL values \>0.85 ([Table 3](#t0015){ref-type="table"}, see asterisks), which account for 12 additional pathogenic *ATP7A* alleles. Diagnostic specificity with a REVEL score cut-off of 0.85 is ≥99%, *i.e.*, false positive rate ≤ 1% \[[@bb0115]\]. Addition of these 12 missense alleles to the four complete LOF alleles, increases the predicted birth prevalence of Menkes disease and other ATP7A-related disorders to 1 in 8664 live male births.Table 3Other Potential Disease-Causing *ATP7A* Missense Variants in gnomAD (v2.1.1).Table 3Variant (hg19/GRCh37) and protein change (NM_000052.7)Variant TypeAllele Number DetectedREVELCADD1.X-77266679-G-C p.(G626R)\*Missense30.9629\*26.02.X-77268415-G-A p.(A738T)Missense10.568025.93.X-77268445-G-A p.(V748I)Missense50.727926.44.X-77268454-G-A p.(V751M)Missense30.694926.55.X-77268516-G-C p.(E771D)Missense10.725022.16.X-77268506-C-G p.(A768G)\*Missense20.8799\*26.67.X-77268531-C-A p.(N776K)Missense10.665024.18.X-77268557-C-T p.(P785L)\*Missense10.8980\*28.89.X-77268568-G-A p.(V789M)Missense50.732927.010.X-77270205-C-T p.(T818I)\*Missense10.8640\*27.211.X-77270244-T-A p.(L831H)Missense10.728926.112.X-77271280-A-G p.(Q843R)Missense10.838926.013.X-77284787-G-A p.(R986Q)Missense20.717926.714.X-77284888-G-T p.(A1020S)Missense10.731027.615.X-77284902-A-G p.(I1024M)Missense10.824924.116.X-77284934-C-T p.(A1035V)Missense10.777029.717.X-77294453-C-T p.(R1211W)Missense20.672925.018.X-77296128-A-C p.(K1233T)\*Missense10.9449\*24.419.X-77298098-G-A p(V1273M)\*Missense10.9350\*27.920.X-77298284-A-G p.(R1335G)\*Missense10.8529\*26.621.X-77298821-C-G p.(L1338V)Missense10.838925.622.X-77300985-G-A p.(G1381D)\*Missense10.9340\*30.023.X-77301023-G-T p.(A1394S)Missense10.676928.224.X-77301062-C-A p.(L1407I)Missense10.769925.825.X-77301066-A-C p.(K1408T)Missense10.837027.126.X-77301802-C-T p.(P1413L)\*Missense10.8859\*29.127.X-77301927-C-T p.(R1455W)Missense10.316025.828.X-77301990-A-T p.(S1476C)Missense10.470925.7**Total**43 alleles\<0.85**Total\***12 alleles\>0.85

4. Discussion {#s0020}
=============

Since 1990, we have enrolled 151 classic Menkes disease subjects from the US in our clinical studies of Menkes disease and ATP7A-related phenotypes ([ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0015} [NCT00001262](NCT00001262){#ir0020}, [NCT00811785](NCT00811785){#ir0025}, and [NCT04074512](NCT04074512){#ir0030}). During this timespan, we became aware of at least 30 additional affected subjects in the US. Coupled with results from the present study, this suggests an estimated ascertainment of 10.8% \[(151 + 30)/(56 × 30 yr)\] by a single diagnostic and treatment referral center.

Classic Menkes disease typically is suspected at birth only in the context of a known family history, and more often is discovered after symptoms of the illness appear, between 6 and 10 weeks of age \[[@bb0020], [@bb0025], [@bb0030], [@bb0035]\]. Later recognition (between two and ten months of age), after considerable diagnostic odysseys, is also common in our experience. Milder neurological phenotypes, such as Occipital horn syndrome and ATP7A-related distal motor neuropathy, present later in childhood, or in adulthood \[[@bb0050],[@bb0055]\]. All three conditions currently may be significantly under-diagnosed \[[@bb0005],[@bb0045]\]. In addition, subtler and as yet unrecognized clinical or biochemical phenoytpes may be associated with certain *ATP7A* variants, including some presumed pathogenic missense alleles detected in gnomAD ([Table 3](#t0015){ref-type="table"}). The expanded estimate of deleterious *ATP7A* allele frequency based on inclusion of deleterious missense alleles from gnomAD implies as many as 225 newborns with Menkes disease or other ATP7A-related disorders per year in the US alone.

Prior estimates of Menkes disease incidence varied from 1 in 40,000, to 1 in 254,000, to 1 in 354,507 \[[@bb0005], [@bb0010], [@bb0015]\]. These estimates represented period prevalences based on identified cases of Menkes disease and birth data from Australia, western Europe (Denmark, France, The Netherlands, United Kingdom and West Germany), and Japan, respectively. Several factors may contribute to under-ascertainment of Menkes disease and its variants. These include disparities in access to pediatric medical care and/or tertiary care genetic diagnostic centers, the difficulty for medical professionals in recognizing or suspecting the diagnosis, premature death of affected subjects, and pregnancy losses or elective terminations related to Menkes disease. Miscarriage is a notoriously difficult metric to assess accurately and is estimated to occur in as many as 10--15% of pregnancies in the developed world \[[@bb0140]\]. We are unaware of an increased rate of miscarriage or stillbirth among known female heterozygotes for Menkes disease and its variants.

Newborn screening (NBS) for Menkes disease, including DNA-based approaches, is under consideration based on the availability of Copper Histidinate \[[@bb0085],[@bb0090]\], an investigational therapy being developed for this condition. Future implementation of NBS is anticipated to identify newborns at-risk for a medically actionable condition during the pre-symptomatic phase of the illness. All infants with *ATP7A* variants found at NBS could be evaluated to confirm the presence of Menkes disease by a rapid and reliable assay for plasma catecholamine levels \[[@bb0085],[@bb0145]\]. This assay, while not readily convertible to a platform suitable for neurochemical-based NBS using dried blood spots, will provide a superb secondary test to identify subjects for whom immediate medical treatment is appropriate. Both Menkes disease and Occipital horn syndrome feature distinctively abnormal plasma catechol profiles \[[@bb0050],[@bb0085],[@bb0145]\], whereas patients with ATP7A-related isolated distal motor neuropathy do not \[[@bb0055]\]. While the latter patients are not candidates for CuHis treatment, other subjects identified with *ATP7A* variants ([Table 3](#t0015){ref-type="table"}**)** that alter proper copper metabolism may benefit from it. Follow-up testing for abnormal serum copper and ceruloplasmin levels and/or distinctive plasma neurochemical levels may be relevant for male newborns identified with [Table 3](#t0015){ref-type="table"} variants.

*In silico* programs such as Polyphen-2 have an estimated predictive accuracy of 65--80%, resulting in overestimation of missense changes as deleterious, and may not be as reliable at predicting missense variants with a milder effects \[[@bb0150]\]. In contrast, the REVEL and CADD ensemble approaches to assessing pathogenicity are considered far more reliable \[[@bb0115],[@bb0120]\]. Since missense mutations are rarely responsible for Duchenne (or Becker) muscular dystrophy, we did not extend our gnomAD analysis to possible pathogenic missense alleles at the DMD locus \[[@bb0155]\].

The current analysis reinforces the value of population-based genomics in assessing the true incidence of rare inherited disorders that may be difficult to ascertain for various reasons. We hypothesize that a newborn screening pilot study for Menkes disease will confirm a higher than previously estimated prevalence, as noted for Pompe disease and other rare inherited disorders following implementation of newborn screening \[[@bb0060], [@bb0065], [@bb0070], [@bb0075],[@bb0160]\]. Earlier detection of *ATP7A* variants by newborn screening would contribute to considerably reduced morbidity and mortality from classic Menkes disease and related conditions \[[@bb0085],[@bb0090]\] and alleviate parent suffering.
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[^1]: Source: gnomAD.
